TRANSFORM and ZUMA-7: A Discussion on Efficacy and Safety of CAR T in R/R DLBCL
Panelists discuss the efficacy and safety of chimeric antigen receptor T-cell (CAR T) therapy in relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) and compare the data collected from the TRANSFORM and ZUMA-7 trials, including information regarding the patient control group, patient population prior response, crossovers of both trials, and vein-to-vein time.
EP: 1.DLBCL in Focus: Transforming Outcomes With CAR T Therapy
EP: 2.Beyond Salvage: When to Move to CAR T in Relapsed DLBCL
EP: 3.Tailoring Therapy: Patient-Specific Decision-Making in Relapsed DLBCL
EP: 4.TRANSFORM and ZUMA-7: A Discussion on Efficacy and Safety of CAR T in R/R DLBCL
EP: 5.CAR T in the Real World: Clinician Perspectives on Outcomes, Toxicity, and Patient Management
EP: 6.Rethinking CAR T Timing: Insights on CAR T Efficacy and Patient Selection
EP: 7.Personalizing CAR T: Making the Right Call for Each Patient
EP: 8.Auto-SCT or CAR T? A Case-Based Discussion in Relapsed DLBCL
EP: 9.Transplant-Eligible, CAR T Considered: How Do We Decide?
EP: 10.CAR T in High-Risk DLBCL: Making the Right Choice in Aggressive Disease
EP: 11.The Future of DLBCL: Innovations in Therapy and Patient Care
Prolaris in Practice: Guiding ADT Benefits, Clinical Application, and Expert Insights From ACRO 2025
April 15th 2025Steven E. Finkelstein, MD, DABR, FACRO discuses how Prolaris distinguishes itself from other genomic biomarker platforms by providing uniquely actionable clinical information that quantifies the absolute benefit of androgen deprivation therapy when added to radiation therapy, offering clinicians a more precise tool for personalizing prostate cancer treatment strategies.
Rare Primary ALK-Positive Anaplastic Large Cell Lymphoma of the Central Nervous System
Anaplastic large cell lymphoma is a rapidly growing and aggressive hematological malignancy. This case highlights the rarity of isolated intradural extramedullary manifestations in the pediatric population.
